Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Corvus Pharma Com (CRVS)

3.17   -0.07 (-2.16%) 03-03 16:09
Open: 3.28 Pre. Close: 3.24
High: 3.335 Low: 3.13
Volume: 821,479 Market Cap: 120M
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase Ib/2 clinical trial for adenosine, an immune checkpoint. The company is also developing CPI-006, an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial that inhibits the production of adenosine and stimulate various immune cells, as well as Phase I clinical trial of CPI-006 for COVID-19; an antagonist of the adenosine A2B receptor; and CPI-818, a small molecule covalent inhibitor of interleukin-2-inducible T-cell kinase, that is Phase I/Ib clinical trial. Corvus Pharmaceuticals, Inc. also entered into a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was founded in 2014 and is based in Burlingame, California.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 3.462 - 3.496 3.496 - 3.516
Low: 3.132 - 3.174 3.174 - 3.199
Close: 3.192 - 3.26 3.26 - 3.301

Technical analysis

as of: 2021-03-03 3:26:10 PM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 5.06     One year: 5.93
Support: Support1: 3.13    Support2: 2.60
Resistance: Resistance1: 4.34    Resistance2: 5.08
Pivot: 3.71
Moving Average: MA(5): 3.38     MA(20): 3.85
MA(100): 3.95     MA(250): 3.60
MACD: MACD(12,26): -0.16     Signal(9): -0.07
Stochastic oscillator: %K(14,3): 3.63     %D(3): 5.25
RSI: RSI(14): 39.05
52-week: High: 6.88  Low: 1.01  Change(%): -10.7
Average Vol(K): 3-Month: 82460  10-Days: 227728

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.
CRVS has closed above bottom band by 14.2%. Bollinger Bands are 123.9% wider than normal. The large width of the bands suggest high volatility as compared to CRVS's normal range. The bands have been in this wide range for 15 bars. This is a sign that the current trend might continue.

Headline News

Mon, 01 Mar 2021
Do Analysts Agree Monday on Corvus Pharmaceuticals Inc (CRVS) Stock's Target Price? - InvestorsObserver

Fri, 26 Feb 2021
Do Traders Think Corvus Pharmaceuticals Inc (CRVS) Can Turn Around Friday? - InvestorsObserver

Thu, 25 Feb 2021
Is Corvus Pharmaceuticals Inc (CRVS) a Smart Choice in Biotechnology Thursday? - InvestorsObserver

Fri, 19 Feb 2021
Corvus Pharma surges after an insider purchase of ~1.3M shares - Seeking Alpha

Wed, 17 Feb 2021
Corvus Pharmaceuticals Announces Closing of Public Offering of Common Stock - GlobeNewswire

Fri, 12 Feb 2021
How Does Corvus Pharmaceuticals Inc (CRVS) Stock Rank on Wall Street? - InvestorsObserver

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency n/a
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Underperform Price to Earnings: Underperform
Return on Equity: Underperform Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 28
Shares Float (M) 15
% Held by Insiders 4.98
% Held by Institutions 63.75
Shares Short (K) 1,230
Shares Short P. Month (K) 1,240

Stock Financials

EPS -1.509
EPS Est This Year -3.180
EPS Est Next Year -3.410
Book Value (p.s.) 1.510
Profit Margin
Operating Margin
Return on Assets (ttm) -38.2
Return on Equity (ttm) -72.3
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.) -1.592
Qtrly Earnings Growth
Operating Cash Flow (M) -35
Levered Free Cash Flow (M) -19

Stock Valuations

PE Ratio -2.13
PEG Ratio
Price to Book value 2.13
Price to Sales
Price to Cash Flow -2.57

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.